Clinical Trials Directory

Trials / Unknown

UnknownNCT02065960

Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer

Feasibility Study of the Role of Stereotactic Body Radiotherapy for the Treatment of Early Stage Breast Cancer

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
32 (estimated)
Sponsor
Juravinski Cancer Center · Academic / Other
Sex
Female
Age
70 Years
Healthy volunteers
Not accepted

Summary

Most women with early breast cancer are treated with breast conserving therapy (BCT), consisting of breast conserving surgery (surgery to remove the cancer itself) followed by radiation to the breast. This treatment can take time and is associated with its own side effect profile. An innovative radiation technique called stereotactic body radiotherapy (SBRT) can deliver large doses of radiation precisely to the tumour while avoiding critical organs, therefore destroying the cancer and avoiding surgery altogether. SBRT has been successfully used for a number of cancers and it is proposed that it could be used to eradicate breast cancer. This feasibility study will investigate the feasibility and safety of treatment using SBRT in women with early stage breast cancer. Thirty-two women age 70 years or older with early breast cancer will be treated with SBRT (5 treatments) followed by breast conserving surgery and hormonal therapy. An MRI and breast conserving surgery will be performed at 8-12 weeks after radiation to assess response to treatment. The primary outcome of the study will be feasibility, meaning the ability to deliver radiation treatment as planned. Secondary outcomes will include treatment related toxicity and pathological response. If this study shows that SBRT can be used to treat patients primarily, it will lead to further evaluation of SBRT for early breast cancer.

Conditions

Interventions

TypeNameDescription
RADIATIONStereotactic body radiotherapy (SBRT)

Timeline

Start date
2014-02-01
Primary completion
2016-06-01
Completion
2020-06-01
First posted
2014-02-19
Last updated
2015-03-31

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02065960. Inclusion in this directory is not an endorsement.